IL6 and ovarian cancer: Since upregulation of A2B and subsequent activation of IL‐6‐STAT3 signalling endows ovarian cancer cells with Olaparib resistance, we wondered if inhibition of A2B‐IL‐6‐STAT3 axis could overcome such resistance and prevent tumour cell growth.